Discovery of Potent Antihypertensive Ligands Substituted Imidazolyl Biphenyl Sulfonylureas Analogs as Angiotensin II AT1 Receptor Antagonists by Molecular Modelling Studies

  • Mukesh C. SharmaEmail author


To elucidate the structural properties required for antihypertensive activity, three different molecular modeling techniques; two-dimensional Quantitative structure activity relationship (2D-QSAR), Group-Based Quantitative structure activity relationship (G-QSAR), and three-dimensional Quantitative structure activity relationship (3D-QSAR) studies have been carried out on a series of substituted imidazolyl biphenyl sulfonylureas derivatives. Multiple linear regressions methodology, viz. variable simulated annealing (SA) and stepwise (SW) methods, was applied to derive models which were further validated for statistical significance and predictive ability by internal and external validation. The best 2D-QSAR model was selected, having showed best predictability of activity with cross validated value (q2) = 0.7866, coefficient of determination (r2) = 0.8003. The r2 pred value of 0.7651 indicates predictability of test set analogues and reveals a significant and robust model and best G-QSAR model having r2 = 0.7459 and q2 = 0.6712 with pred_r2 = 0.7105 was developed by SA -MLR. Using k-nearest neighbour (kNN) approach, various 3D QSAR models were generated and selected on the basis of q2 and predictive r2 values. The analyzed best 3D-QSAR model revealed a good fit, having r2 value of 0.8240 and q2 value of 0.7523. The predictive power of the model generated was validated using a test set comprising molecules with pred_r2 value of 0.7299. The results of two-dimensional QSAR, Group based QSAR showed that a combination of revealed the key role of Baumann’s alignment independent topological descriptors along with other descriptors such as the number of hydrogen bond acceptors, hydrogen bond donors, rotatable bonds indices properties and auto-correlation descriptors of different atomic properties could be explored to design potent antihypertensive agents. Finally, it is hoped that the work presented here will play an important role in understanding the relationship of physiochemical parameters with structure and biological activity.

Key words

imidazolyl QSAR group based-QSAR k-nearest neighbour (kNN) multiple linear regressions (MLR) anti-hypertensive agents 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



The author wishes to express gratitude to V-life Science Technologies Pvt. Ltd for providing the software for the study.


  1. [1]
    Ajmani S, Jadhav K, Kulkarni SA (2006) Three-Dimensional QSAR using the k-Nearest Neighbor method and its interpretation. J Chem Inf Model 46: 24–31.CrossRefGoogle Scholar
  2. [2]
    Ajmani S, Jadhav K, Kulkarni SA (2009) Group-Based QSAR (GQSAR): mitigating interpretation challenges in QSAR. QSAR Comb Sci 28: 36–41.CrossRefGoogle Scholar
  3. [3]
    Campbell DJ (1978) Circulating and tissue angiotensin systems. J Clin Invest 79: 1–6.CrossRefGoogle Scholar
  4. [4]
    Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA) 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110: 5959–5967.CrossRefGoogle Scholar
  5. [5]
    Clark M, Cramer RD III, Van ON (1989) Validation of the general purpose tripos 5.2 force field. J Comput Chem 10: 982–1012.CrossRefGoogle Scholar
  6. [6]
    Carini DJ, Duncia J V, Aldrich PE, Chiu A T, Johnson AL, Pierce M E, et al., (1991) Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl) imidazoles as potent, orally active antihypertensives. J Med Chem 34: 2525.CrossRefGoogle Scholar
  7. [7]
    Deprez P, Bertrand H, Alain C, Jean-Paul V, Michel F, Jacques G (1995) Balanced AT1 and AT2 angiotensin II antagonists. II. Potent 5 α-hydroxyacid imidazolyl biphenyl sulfonylureas. Bioorg Med Chem Lett 5 (22): 2611–2616.CrossRefGoogle Scholar
  8. [8]
    Dzau VJ, Pratt RE. Renin-Angiotensin System: Biology, Physiology and Pharmacology. In The Heart and Cardiovascular System; Fozzard, H. A., Haber, E., Jennings, R. B., Katz, A. M., Morgan, H. E., Eds.; Raven Press: New York, 1986; pp. 1631–1662.Google Scholar
  9. [9]
    Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 36: 3219–3228.CrossRefGoogle Scholar
  10. [10]
    Golbraikh A, Tropsha A (2002a) Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J Comput Aided Mol Des 16: 357–369.CrossRefGoogle Scholar
  11. [11]
    Golbraikh A, Tropsha A (2002b) Beware of Q2, J Mole Grap Model 20: 269–276.CrossRefGoogle Scholar
  12. [12]
    Gao H, Hansch C (1996) QSAR of p450 oxidation: on the value of comparing kcat and Km with kcat/Km. Drug Metab Rev 28: 513–526.CrossRefGoogle Scholar
  13. [13]
    Halgren TA (1996) Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94. J Comput Chem 17: 553–586.CrossRefGoogle Scholar
  14. [14]
    Johnston CI, Franz V (1992) Lecture Renin angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hyperten 10: S13–S26.Google Scholar
  15. [15]
    Joseph MP, Maigret B, Bonnafous JC, Marie J, Scheraga HA (1995) A computer modeling postulated mechanism for angiotensin II receptor activation. J Prot Chem 14: 381–398.CrossRefGoogle Scholar
  16. [16]
    Kubinyi H, Mannhold R, Krogsgaard LR, Timmerman HE. Methods and principles in medicinal chemistry, vol 1. VCH, Weinheim, 1993: pp 91–95.Google Scholar
  17. [17]
    Kubo K, Kohara Y, Imamiya E, Sugiura Y, Inada Y, Furukawa Y, Nishikawa K, Naka T (1993) Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids. J Med Chem 36: 2182.CrossRefGoogle Scholar
  18. [18]
    Lien EJ, Gao H (1995) QSAR analysis of skin permeability of various drugs in man as compared in vivo and in vitro studies in rodents. Pharm Res 12: 583–587.CrossRefGoogle Scholar
  19. [19]
    McAreavey D, Robertson J I S (1990) Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 40: 326.CrossRefGoogle Scholar
  20. [20]
    Murphy T J, Alexander R W, Griendling K K, Runge MS, Bernstein K E (1991) Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351: 233–236.CrossRefGoogle Scholar
  21. [21]
    Ondetti M A, Rubin A, Cushman DW (1977) Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196: 441.CrossRefGoogle Scholar
  22. [22]
    Plummer EL (1995) Successful application of the QSAR paradigm in discovery programs. In: Hansch C, Fujita T (eds) Classical and three-dimensional QSAR in agrochemistry. American Chemical Society, Washington, DC.Google Scholar
  23. [23]
    Ries UJ, Mihm G, Narr B, Hasselbach KM, Wittneben H, Entzeroth M, VanMeel J C A, Wienen W, Hauel NH (1993) 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. J Med Chem 25: 4040.CrossRefGoogle Scholar
  24. [24]
    Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray J J, Hasegawa M, et al. (1991) Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 351: 230–233.CrossRefGoogle Scholar
  25. [25]
    VLife MDS 3.5 (2008) Molecular design suite. Vlife Sciences Technologies Pvt. Ltd., Pune.Google Scholar
  26. [26]
    Wexler R R, Greenlee W J, Irvin JD, Goldberg MR, Prendergast K, Smith RD, et al. (1996) Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem 39: 625.CrossRefGoogle Scholar

Copyright information

© International Association of Scientists in the Interdisciplinary Areas and Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Drug Research Laboratory, School of PharmacyDevi Ahilya UniversityIndia

Personalised recommendations